Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science ...

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific Officer, President, Pfizer Research & Development, ...

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the ...

Welcome to this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, leaders and investors straight to your inbox.

SARS-CoV-2 is a positive-sense single-stranded RNA virus. It is contagious in humans and is the cause of the coronavirus disease 2019 (COVID-19). Hallmarks of post-acute consequences of SARS-CoV-2 ...

With the acute phase of the Covid-19 pandemic fading even as the coronavirus persists and evolves, a new normal is taking shape around the world. In a small study, patients with the syndrome were ...

Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads to ...

How would the world cope if another infectious disease with pandemic potential were to emerge, as COVID-19 did five years ago? The answer is, we simply don’t know. In some respects, there are ...

Hair loss can be caused by various factors including nutritional deficiencies, stress, certain medications, and conditions like alopecia areata. Childbirth can also trigger hair loss due to ...

Microneedling for hair loss is a procedure that involves puncturing the top layer of skin with tiny needles to stimulate hair growth. The treatment is effective for many people with male-pattern ...

And now, researchers are thinking they may also be causing a type of hair loss called alopecia areata, an autoimmune condition that “attacks” the hair follicles, causing patches of hair loss.

Q32 Bio has put a stop to a Phase II trial of its former lead renal disease candidate as it pivots focus over to its alopecia areata treatment, bempikibart, amid a corporate restructure and job cuts.